A molecular case report: Functional assay of tyrosine kinase inhibitors in cells from a patient's primary renal cell carcinoma

Molly Kulesz-Martin, James Lagowski, Susan Olson, Aaron Wortham, Toni West, George Thomas, Christopher Ryan, Jeffrey Tyner

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Current therapies for renal cell carcinoma favor vascular endothelial growth factor receptor (VEGF-R) tyrosine kinase (TK) inhibitors (TKIs). In theory, these are most applicable in tumors that have lost VHL-with subsequent stabilization of HIF and upregulation of VEGF. A subset of patients harbor primary-refractory disease, as in this case, where there was no evidence for loss of VHL or chromosome 3p. We evaluated molecular targeted agents in viable tumor cells cultured from a patient's clear cell renal cell carcinoma (RCC). Of 66 agents, only dasatinib, an inhibitor of Src tyrosine kinase, strongly reduced viability of the patient's cultured kidney tumor cells. Immunostaining of the original primary tumor revealed strong positivity for VHL and Src protein expression. Functional evaluation of a patient's tumor cells appears feasible in the setting of RCC.

Original languageEnglish (US)
Pages (from-to)95-99
Number of pages5
JournalCancer Biology and Therapy
Volume14
Issue number2
DOIs
StatePublished - Feb 2013

Fingerprint

Renal Cell Carcinoma
Protein-Tyrosine Kinases
Cultured Tumor Cells
Neoplasms
Vascular Endothelial Growth Factor Receptor
src-Family Kinases
Vascular Endothelial Growth Factor A
Up-Regulation
Chromosomes
Kidney
Proteins
Therapeutics

Keywords

  • Molecular targeted therapy
  • Renal cell carcinoma
  • Tyrosine kinase

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Molecular Medicine
  • Pharmacology

Cite this

@article{1c4499d3a0824e72b2062755b8765d91,
title = "A molecular case report: Functional assay of tyrosine kinase inhibitors in cells from a patient's primary renal cell carcinoma",
abstract = "Current therapies for renal cell carcinoma favor vascular endothelial growth factor receptor (VEGF-R) tyrosine kinase (TK) inhibitors (TKIs). In theory, these are most applicable in tumors that have lost VHL-with subsequent stabilization of HIF and upregulation of VEGF. A subset of patients harbor primary-refractory disease, as in this case, where there was no evidence for loss of VHL or chromosome 3p. We evaluated molecular targeted agents in viable tumor cells cultured from a patient's clear cell renal cell carcinoma (RCC). Of 66 agents, only dasatinib, an inhibitor of Src tyrosine kinase, strongly reduced viability of the patient's cultured kidney tumor cells. Immunostaining of the original primary tumor revealed strong positivity for VHL and Src protein expression. Functional evaluation of a patient's tumor cells appears feasible in the setting of RCC.",
keywords = "Molecular targeted therapy, Renal cell carcinoma, Tyrosine kinase",
author = "Molly Kulesz-Martin and James Lagowski and Susan Olson and Aaron Wortham and Toni West and George Thomas and Christopher Ryan and Jeffrey Tyner",
year = "2013",
month = "2",
doi = "10.4161/cbt.22960",
language = "English (US)",
volume = "14",
pages = "95--99",
journal = "Cancer Biology and Therapy",
issn = "1538-4047",
publisher = "Landes Bioscience",
number = "2",

}

TY - JOUR

T1 - A molecular case report

T2 - Functional assay of tyrosine kinase inhibitors in cells from a patient's primary renal cell carcinoma

AU - Kulesz-Martin, Molly

AU - Lagowski, James

AU - Olson, Susan

AU - Wortham, Aaron

AU - West, Toni

AU - Thomas, George

AU - Ryan, Christopher

AU - Tyner, Jeffrey

PY - 2013/2

Y1 - 2013/2

N2 - Current therapies for renal cell carcinoma favor vascular endothelial growth factor receptor (VEGF-R) tyrosine kinase (TK) inhibitors (TKIs). In theory, these are most applicable in tumors that have lost VHL-with subsequent stabilization of HIF and upregulation of VEGF. A subset of patients harbor primary-refractory disease, as in this case, where there was no evidence for loss of VHL or chromosome 3p. We evaluated molecular targeted agents in viable tumor cells cultured from a patient's clear cell renal cell carcinoma (RCC). Of 66 agents, only dasatinib, an inhibitor of Src tyrosine kinase, strongly reduced viability of the patient's cultured kidney tumor cells. Immunostaining of the original primary tumor revealed strong positivity for VHL and Src protein expression. Functional evaluation of a patient's tumor cells appears feasible in the setting of RCC.

AB - Current therapies for renal cell carcinoma favor vascular endothelial growth factor receptor (VEGF-R) tyrosine kinase (TK) inhibitors (TKIs). In theory, these are most applicable in tumors that have lost VHL-with subsequent stabilization of HIF and upregulation of VEGF. A subset of patients harbor primary-refractory disease, as in this case, where there was no evidence for loss of VHL or chromosome 3p. We evaluated molecular targeted agents in viable tumor cells cultured from a patient's clear cell renal cell carcinoma (RCC). Of 66 agents, only dasatinib, an inhibitor of Src tyrosine kinase, strongly reduced viability of the patient's cultured kidney tumor cells. Immunostaining of the original primary tumor revealed strong positivity for VHL and Src protein expression. Functional evaluation of a patient's tumor cells appears feasible in the setting of RCC.

KW - Molecular targeted therapy

KW - Renal cell carcinoma

KW - Tyrosine kinase

UR - http://www.scopus.com/inward/record.url?scp=84873439685&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873439685&partnerID=8YFLogxK

U2 - 10.4161/cbt.22960

DO - 10.4161/cbt.22960

M3 - Article

C2 - 23192268

AN - SCOPUS:84873439685

VL - 14

SP - 95

EP - 99

JO - Cancer Biology and Therapy

JF - Cancer Biology and Therapy

SN - 1538-4047

IS - 2

ER -